Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 1/20 | 0.36 |
| ▸ | SCN4A | P35499 | 1/20 | 0.36 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.36 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.36 |
| ▸ | SCN11A | Q9UI33 | 1/20 | 0.36 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.36 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4653058 | 0.93 | SCN1A (0.41) | SCN1ASCN4ASCN7AKCNH2SCN5A | |
| SCHEMBL29142963 | 0.93 | SCN1A (0.36) | SCN1ASCN4ASCN7AKCNH2SCN5A | |
| SCHEMBL6079568 | 0.90 | SCN1A (0.39) | SCN1ASCN4ASCN7AKCNH2SCN5A | |
| SCHEMBL1814570 | 0.90 | SCN1A (0.42) | SCN1ASCN4ASCN7AKCNH2SCN5A | |
| SCHEMBL4655181 | 0.90 | SCN1A (0.32) | SCN1ASCN4ASCN7AKCNH2SCN5A | |
| SCHEMBL7164910 | 0.90 | SCN1A (0.37) | SCN1ASCN4ASCN7AKCNH2SCN5A | |
| SCHEMBL2993610 | 0.87 | SCN1A (0.41) | SCN1ASCN4ASCN7AKCNH2SCN5A | |
| SCHEMBL4654056 | 0.87 | SCN1A (0.31) | SCN1ASCN4ASCN7AKCNH2SCN5A | |
| SCHEMBL181178 | 0.87 | SCN1A (0.41) | SCN1ASCN4ASCN7AKCNH2SCN5A | |
| SCHEMBL4697737 | 0.87 | SCN1A (0.41) | SCN1ASCN4ASCN7AKCNH2SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2513086-B1 | NOVEL ANTAGONISTS FOR CCR2 AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2015-04-29 | — | — | EP | claimed |
| EP-0361341-A2 | Therapeutics for aids based on inhibitors of HIV protease | MILES INC. (US) | 1990-04-04 | — | — | EP | claimed |
| WO-2020247608-A1 | SMALL MOLECULE INHIBITORS OF A PROTEIN COMPLEX | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-12-10 | — | — | WO | disclosed |
| US-20190127772-A1 | ENZYMATIC GLYCOSYLATION OF STEVIOL GLYCOSIDES AND OTHER COMPOUNDS WITH GLUCOSE-1-PHOSPHATE | CODEXIS INC (US) | 2019-05-02 | — | — | US | disclosed |
| EP-2887943-A1 | NOVEL 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES | Virostatics Srl (IT) | 2015-07-01 | — | — | EP | disclosed |
| WO-2014031937-A1 | NOVEL 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES | VIROSTATICS SRL (IT) | 2014-02-27 | — | — | WO | disclosed |
| WO-2010072712-A1 | BIARYL BENZYLAMINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-01 | — | — | WO | disclosed |
| EP-2104671-A2 | SUBSTITUTED HETEROCYCLYLCARBONYLAMINO-ACETIC-ACID-DERIVATIVES AS INHIBITORS OF BACTERIAL HEPTOSE SYNTHESIS, METHODS FOR THEIR PREPARATION AND BIOLOGICAL APPLICATIONS OF SAID INHIBITORS | Mutabilis SA (FR) | 2009-09-30 | — | — | EP | disclosed |
| WO-2008038136-A2 | SUBSTITUTED HETEROCYCLYLCARBONYLAMINO-ACETIC-ACID-DERIVATIVES AS INHIBITORS OF BACTERIAL HEPTOSE SYNTHESIS, METHODS FOR THEIR PREPARATION AND BIOLOGICAL APPLICATIONS OF SAID INHIBITORS | MUTABILIS SA (FR) | 2008-04-03 | — | — | WO | disclosed |
| US-20070099924-A1 | Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication | JANSSEN SCIENCES IRELAND UC (IE) | 2007-05-03 | — | — | US | disclosed |
| US-20070043010-A1 | Quinazoline derivatives | ASTRAZENECA UK LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| EP-0958296-A1 | NOVEL HETEROCYCLIC COMPOUNDS PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED DISEASES | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1999-11-24 | — | — | EP | disclosed |
| US-5696084-A | Amino-lipopetide antifungal agents | ABBOTT LABORATORIES (US) | 1997-12-09 | — | — | US | disclosed |
| WO-1997041097-A2 | NOVEL HETEROCYCLIC COMPOUNDS PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED DISEASES | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1997-11-06 | — | — | WO | disclosed |
| EP-0361341-A2 | Therapeutics for aids based on inhibitors of HIV protease | MILES INC. (US) | 1990-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099924-A1 | Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-2, H1-4 | SCN1A 613/4885SCN4A 279/4885SCN7A 1082/4885 |
| US-20070043010-A1 | Quinazoline derivatives | ERBB2, ABL1, EGFR | SCN1A 2683/4885SCN4A 3307/4885SCN7A 2898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.